These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 10382844

  • 1. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
    Reist CJ, Foulon CF, Alston K, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 1999 May; 26(4):405-11. PubMed ID: 10382844
    [Abstract] [Full Text] [Related]

  • 2. N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At.
    Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2003 May; 30(4):351-9. PubMed ID: 12767391
    [Abstract] [Full Text] [Related]

  • 3. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
    Reist CJ, Garg PK, Alston KL, Bigner DD, Zalutsky MR.
    Cancer Res; 1996 Nov 01; 56(21):4970-7. PubMed ID: 8895752
    [Abstract] [Full Text] [Related]

  • 4. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.
    Larsen RH, Murud KM, Akabani G, Hoff P, Bruland OS, Zalutsky MR.
    J Nucl Med; 1999 Jul 01; 40(7):1197-203. PubMed ID: 10405142
    [Abstract] [Full Text] [Related]

  • 5. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.
    Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2002 Jan 01; 29(1):1-11. PubMed ID: 11786270
    [Abstract] [Full Text] [Related]

  • 6. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
    Reist CJ, Archer GE, Wikstrand CJ, Bigner DD, Zalutsky MR.
    Cancer Res; 1997 Apr 15; 57(8):1510-5. PubMed ID: 9108453
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.
    Foulon CF, Welsh PC, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2001 Oct 15; 28(7):769-77. PubMed ID: 11578897
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
    Hens M, Vaidyanathan G, Welsh P, Zalutsky MR.
    Nucl Med Biol; 2009 Feb 15; 36(2):117-28. PubMed ID: 19217523
    [Abstract] [Full Text] [Related]

  • 12. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Hens M, Vaidyanathan G, Zhao XG, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2010 Oct 15; 37(7):741-50. PubMed ID: 20870149
    [Abstract] [Full Text] [Related]

  • 13. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent.
    Reist CJ, Batra SK, Pegram CN, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 1997 Oct 15; 24(7):639-47. PubMed ID: 9352535
    [Abstract] [Full Text] [Related]

  • 14. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
    Shankar S, Vaidyanathan G, Kuan CT, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2006 Jan 15; 33(1):101-10. PubMed ID: 16459265
    [Abstract] [Full Text] [Related]

  • 15. Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment.
    Garg PK, Harrison CL, Zalutsky MR.
    Cancer Res; 1990 Jun 15; 50(12):3514-20. PubMed ID: 2340501
    [Abstract] [Full Text] [Related]

  • 16. Monoclonal antibody F(ab')2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates: in vivo comparison of iodinated and astatinated fragments.
    Vaidyanathan G, Affleck D, Zalutsky MR.
    Nucl Med Biol; 1994 Jan 15; 21(1):105-10. PubMed ID: 9234271
    [Abstract] [Full Text] [Related]

  • 17. Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac.
    Yordanov AT, Garmestani K, Zhang M, Zhang Z, Yao Z, Phillips KE, Herring B, Horak E, Beitzel MP, Schwarz UP, Gansow OA, Plascjak PS, Eckelman WC, Waldmann TA, Brechbiel MW.
    Nucl Med Biol; 2001 Oct 15; 28(7):845-56. PubMed ID: 11578907
    [Abstract] [Full Text] [Related]

  • 18. SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies.
    Vaidyanathan G, White BJ, Affleck DJ, Zhao XG, Welsh PC, McDougald D, Choi J, Zalutsky MR.
    Bioorg Med Chem; 2012 Dec 15; 20(24):6929-39. PubMed ID: 23159039
    [Abstract] [Full Text] [Related]

  • 19. A polar substituent-containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[131I]iodobenzoate ([131I]SGMIB).
    Vaidyanathan G, Affleck DJ, Li J, Welsh P, Zalutsky MR.
    Bioconjug Chem; 2001 Dec 15; 12(3):428-38. PubMed ID: 11353542
    [Abstract] [Full Text] [Related]

  • 20. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
    Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR.
    Cancer Res; 1995 Oct 01; 55(19):4375-82. PubMed ID: 7671250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.